Table 2.
Treatment exposure and dose modification.
| Parameter | Renal Impairment (n = 66) | Elderly (n = 287) | Diabetes (n = 107) | Poor PS (n = 42) |
|---|---|---|---|---|
| Treatment Exposure | ||||
| No. of cycles, median (range) | 5.0 (1.0–26.0) | 6.0 (1.0–48.0) | 6.0 (1.0–34.0) | 4.0 (1.0–18.0) |
| Patients who received ≤ 6 cycles, n (%) | 48 (72.7) | 198 (69.0) | 64 (59.8) | 32 (76.2) |
| Dose intensity, median (range) | ||||
| Carboplatin, mg•min/ml/wk | 1.9 (0.2–201.7) | 1.4 (0.1–226.9) | 1.4 (0.3–255.6) | 1.4 (0.4–226.0) |
| nab-Paclitaxel, mg/m2/wk | 66.3 (26.7–102.4) | 62.2 (14.5–116.7) | 63.6 (14.5–100.8) | 55.1 (31.4–100.0) |
| Relative dose intensity, median (range), % | ||||
| Carboplatin | 87.6 (19.6–116.7) | 82.5 (19.6–400.0) | 83.2 (21.6–125.0) | 83.8 (21.6–110.3) |
| nab-Paclitaxel | 76.9 (26.7–102.4) | 72.4 (19.3–155.6) | 74.1 (19.3–105.2) | 79.9 (47.1–100.0) |
| Cumulative dose, median (range) | ||||
| Carboplatin, mg•min/ml | 30.0 | 24.0 | 24.0 | 19.5 |
| (5.0–14252.0) | (5.0–7974.0) | (5.0–9466.0) | (5.0–1840.0) | |
| nab-Paclitaxel, mg/m2 | 1037.5 | 1200.0 | 1300.0 | 600.0 |
| (100.0–5150.0) | (100.0–9550.0) | (100.0–6675.0) | (100.0–3200.0) | |
| Dose Modification | ||||
| Patients with ≥ 1 dose reduction, n (%) | ||||
| Carboplatin nab-Paclitaxel |
43 (65.2) 43 (65.2) |
189 (65.9) 200 (69.7) |
65 (60.7) 69 (64.5) |
13 (31.0) 15 (35.7) |
| Patients with ≥ 1 dose interruption, n (%) | ||||
| Carboplatin | 0 | 0 | 2 (1.9) | 0 |
| nab-Paclitaxel | 0 | 1 (0.3) | 2 (1.9) | 0 |
| Patients with ≥ 1 dose delay, n (%) | ||||
| Carboplatin | 55 (83.3) | 215 (74.9) | 79 (73.8) | 16 (38.1) |
| nab-Paclitaxel | 64 (97.0) | 245 (85.4) | 93 (86.9) | 20 (47.6) |
ECOG PS, Eastern Cooperative Oncology Group performance status.